Capstone initiates Coverage on Inverness Medical Innovations (IMA) with a Buy
More News related to IMA
- To Manage Weight Over the Holidays, Experts From Alere Say Enjoy, Indulge a Little and Don't Diet!
- OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
- OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
- Alere Secures Prestigious NCQA Accreditation for Wellness & Health Promotion
- OraSure Technologies Announces Settlement of Patent Infringement Lawsuit With Inverness and Church & Dwight
More News related to New Coverage
- United Community Financial (UCFC) and United Bancshares (UBOH) To Sell Findlay, OH Branch to The Union Bank Co.
- GE receives French notice that its Areva bid wasn't chosen
- Health Management Associates (HMA) Completes Acquisition of Sparks Health System
- Wright Medical (WMGI) Reports Favorable Ruling in Stryker (SYK) Patent Infringement Case
- United Rentals (URI) Awarded Purchasing Contracts in Massachusetts and Texas
Capstone initiates coverage on Inverness Medical Innovations (NYSE: IMA) with a Buy. Price target $47.
To see more analyst ratings on IMA Click Here.
Inverness Medical Innovations, Inc. engages in the development, manufacture, and marketing of consumer and professional medical diagnostic products, as well as a range of vitamins and nutritional supplements
Related Categories
New CoverageStocks Mentioned
+0.30Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
